have and Mark. Thank treat a option disease. to the care benefit bring to who and you, may EYSUVIS with I'd begin from prescription to like short-term new eye a eye treatment professionals today patients opportunity to dry therapy we
and pleased market eye the We with disease its COVID-XX the dry throughout are have been performance closely pandemic. tracking
disease the significant the on need disease market of during based of eye of its that EYSUVIS As dry challenging XX, nearly the and market this XX% strength levels even pre-COVID see market. the an prescription times. at to eye is these treat indicates the disrupt eye opportunity to we Symphony patients dry approved, With believe We data. October dry
tried Based our a optometrist. on of an mentioned, and patients affects As to million approximately dry an dry disease market of to eye these eye flares, or on already ophthalmologist dry dry that approximately XX in Mark report care XX% dry individuals the episodic Across therapy, week's treat EYSUVIS, they prescription eye medication. studies, alone, of last only disease. currently suffer estimated prescription FDA approximately have symptoms there of from currently approval XX eye no large and research million people of eye XX% clinical treatment million diagnosed under an never than are XX% were patients the disease. approximately options more have research, diagnosed U.S. been and are patients these prescription approved with of episodic Prior XX of targeted to quantitative the multiple which translates profile with a a
eye week, for made approval episodic that manage therapy made mild for has to the significant to lack have we treat flares research our Our receiving a moderate rapid-acting last care the disease preparing eye professionals progress dry challenging to of it launch. prescription Since in patients. shows
XX XXX which plan representatives sales to support sales through and sales EYSUVIS force, to INVELTYS. We approximately have grow report to begun we ultimately up who will leaders regional both our expanding
eye the the XXXX, and will eye steroid to believe waves: this sales second dry optometrists who pending patients ophthalmologists in end than growing of structure expansion of expansion on approximately COVID-XX two We the prescribing. the for XX% allow will the majority represent to We representatives all treat with who conduct planned call of the pandemic. us this more and status year, and first by XX this dry of
team sales track December. we offers first extended wave virtual representatives to our onboarded and early launch new in host trained and on XX November of in the have full have We a and reps, to meeting to of remain
treatment our end leverage wholesalers by place with pandemic. experienced EYSUVIS proprietary promotional patients. eye The to care expect and to as eye the majority deep activities begin and meet shipping will care when force how sales ophthalmologists professionals amplify XXXX needs, person, technology, taking in to and have disease treat their will educate to experience on flares, of with EYSUVIS, U.S. optometrists engagements in We soon begin professionals eye are dry how to currently ophthalmic the the learned after the our its short-term COVID-XX safely of of continue during we including anticipate this patients
include web to needs range shipping. and However, and we on they'll be so detailing, virtual This speaker online both will of virtual to based us will these sample for allow team and of between in-person our a eye care that professionals. options tactics able virtual engagements, utilize the flex programs sales case-based train ordering
I'd on prescription look steroid. first I FDA-approved only are our specifically EYSUVIS and like of for last move move you forward launch. now to us extremely eye and to we prescription eye first-line we treatment the on signs the through a to excited dry disease. the as product, ocular symptoms to to mentioned initial and We the intended preferred establish short-term dry As week, postsurgical our for therapy of there's believe tremendous twice-daily for opportunity the EYSUVIS INVELTYS, updating progress disease, we deliver as as
increased prescriptions sales In QX compared which was were represents by growth pleased quarter, are as and fewer effort Symphony of on XXXX. second compared quarter-over-quarter procedures, COVID-XX-related for We an XX,XXX to This of driven to of there elective surgeries, announce increase including quarter third approximately primarily XX% of Health, INVELTYS. restrictions reported result to the in the QX. a INVELTYS ocular significant
INVELTYS of in has with XX.X% just the where we share branded pleased share, returning market to that are branded increased were and, has COVID. prior XX, to NRx It We has as steadily shown. about an recovery October achieved the
that up which this up total the and were weeks XX, INVELTYS October weeks compared was of prescriptions only X during prior most the X.X% to versus market market, time. X only X% As recent the the in was branded overall up XX.X%
our for over ongoing they discuss impact these sales. the again COVID very quarter elective which to will or surge long may third While in future call cases that encouraged could we INVELTYS term, now INVELTYS are Mary surges result restrictions by I procedures, bode and the over the financial results. states trends on recognize to turn in reinstating we believe some well
